Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10733092 | PMC |
| http://dx.doi.org/10.1182/bloodadvances.2023011428 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Role of CELMoD Agents in Multiple Myeloma.
Onco Targets Ther
August 2025
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Although recent decades have seen continued improvements in survival for patients with multiple myeloma, the disease remains largely incurable, and most patients will experience relapse and/or become refractory to treatment. There thus remains an urgent unmet need for novel treatments, particularly for those patients with relapsed or refractory multiple myeloma. Novel treatment modalities, such as targeted protein degradation, have attracted particular interest due to their ability to expand the range of druggable protein targets in myeloma cells.
View Article and Find Full Text PDFIntroduction: Ciltacabtagene autoleucel (cilta-cel) is approved for relapsed or refractory multiple myeloma (RRMM). In the CARTITUDE-4 study (NCT04181827), cilta-cel demonstrated superior efficacy versus pomalidomide, bortezomib, and dexamethasone or daratumumab, pomalidomide, and dexamethasone in patients with RRMM after 1-3 prior lines of therapy (LOT). We conducted an indirect treatment comparison to understand the comparative efficacy of cilta-cel versus real-world (RW) physician's choice of treatment for lenalidomide-refractory MM.
View Article and Find Full Text PDFBackground: Early (often continuous) treatment of multiple myeloma (MM) with lenalidomide has become common practice, leading to an increase in lenalidomide-refractory disease.
Methods: We report real-world treatment patterns, health care resource utilization (HCRU), and outcomes for patients with lenalidomide-refractory MM using data from Optum US Claims and Optum electronic health record (EHR) databases with index date from January 2016 to March 2022 (Claims) or December 2021 (EHR). Eligible patients had received 1-3 prior lines of therapy (LOT), including a proteasome inhibitor.
A network meta-analysis of randomized clinical trials in lenalidomide-exposed or -refractory multiple myeloma patients.
ESMO Open
August 2025
Hematology Unit, Department of Onco-Hematology, AO of Cosenza, Cosenza, Italy; Department of Pharmacy, Health and Nutritional Science, University of Calabria, Rende, Italy. Electronic address:
Background: The treatment landscape for relapsed/refractory multiple myeloma (RRMM) is rapidly evolving, particularly for patients exposed or refractory to lenalidomide. With the aim of evaluating the relative efficacy of lenalidomide-free regimens as second-line treatment options, an updated network meta-analysis, incorporating phase II/III randomized controlled trials, has been conducted.
Materials And Methods: A systematic literature search identified eight eligible trials comprising 3952 patients.
[Novel therapeutic approaches for multiple myeloma].
Rinsho Ketsueki
July 2025
Department of Transfusion and Cellular Therapy, Hematology, Hyogo Medical University.
Multiple myeloma has conventionally been treated with three major classes of drugs, including immunomodulatory drugs, proteasome inhibitors and anti-CD38 antibodies, but T-cell redirection therapies (CAR-T cell therapy and bispecific antibodies) targeting B-cell maturation antigen (BCMA), which is highly expressed on the surface of myeloma cells, have now been adopted as a new modality. In Japan, CAR-T therapy is indicated as a third-line treatment for patients who have already received three classes of drugs, and bispecific antibodies are also indicated for patients who have already received three lines of therapy. Regimens combining antibody-drug conjugates targeting BCMA with bortezomib or pomalidomide have also demonstrated efficacy.
View Article and Find Full Text PDF